作者
Christopher J Poole, Helena M Earl, Louise Hiller, Janet A Dunn, Sarah Bathers, Robert J Grieve, David A Spooner, Rajiv K Agrawal, Indrajit N Fernando, A Murray Brunt, Susan M O'Reilly, S Michael Crawford, Daniel W Rea, Peter Simmonds, Janine L Mansi, Andrew Stanley, Peter Harvey, Karen McAdam, Liz Foster, Robert CF Leonard, Christopher J Twelves
发表日期
2006/11/2
期刊
New England Journal of Medicine
卷号
355
期号
18
页码范围
1851-1862
出版商
Massachusetts Medical Society
简介
Background
The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer.
Methods
In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life.
Results
The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin–CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free …
引用总数
学术搜索中的文章
CJ Poole, HM Earl, L Hiller, JA Dunn, S Bathers… - New England Journal of Medicine, 2006